New Hematology CAR-T Grant Program

Johnson & Johnson Innovative Medicine has issued a Request for Proposals focused on implementation science initiatives designed to improve the treatment and care of patients with relapsed or refractory multiple myeloma who may be eligible for CAR T-cell therapy. As part of its broader commitment to advancing independent medical education and improving patient outcomes, the organization supports projects that integrate evidence-based education with real-world clinical practice improvements. These grants emphasize implementation rather than traditional research, focusing on applying existing knowledge to enhance care delivery in community healthcare settings. The purpose of this funding opportunity is to support community-based healthcare organizations in adopting and sustaining evidence-based practices related to CAR T-cell therapy. Projects are expected to combine certified continuing medical education with operational and clinical workflow changes to address barriers to care. The initiative prioritizes proposals that embed educational activities within broader system-level or practice-level strategies, ensuring that training directly translates into improved clinician behavior, care coordination, and patient outcomes. This approach aligns with implementation science principles by emphasizing measurable changes in clinical practice and healthcare systems. Funding supports a wide range of activities aimed at improving access to and appropriate use of CAR T-cell therapies. These include developing mentorship models between experienced CAR T centers and community clinicians, enhancing referral pathways, improving adverse event monitoring and mitigation strategies, training multidisciplinary care teams, implementing remote monitoring technologies, and strengthening patient education and shared decision-making processes. However, funds cannot be used for institutional overhead, salaries, or durable medical equipment, and projects must demonstrate how improvements will be sustained beyond the grant period. Eligibility for this grant includes a broad set of healthcare and educational organizations, such as community cancer centers, academic institutions, teaching hospitals, medical societies, government agencies, and medical education companies. Applications must be submitted through an accredited continuing medical education or continuing education provider, and all proposed projects must offer certified CME or CE credits. Clinicians and organizations without internal CME capabilities are required to partner with an accredited entity to submit an application. Importantly, research-focused proposals are not eligible, as this funding opportunity is strictly intended for implementation and practice improvement initiatives. The application process requires submission through the Johnson & Johnson Cybergrants portal. Applicants must indicate that their submission responds to this specific RFP and include the designated RFP title in both the application and proposal title. Required components include a detailed project design, assessment of need supported by quantitative data, clearly defined goals and objectives, identification of the target audience, evaluation methodology, project timelines, and a comprehensive budget. Proposals must also describe how educational interventions will align with operational changes and how outcomes will be measured using predefined metrics. Applications are due by July 15, 2026. Funded projects are expected to begin on or after September 1, 2026 and may run for up to 18 months. Grantees are required to provide quarterly progress updates and submit a comprehensive final report at the conclusion of the project. This report must include data on educational reach and engagement, changes in clinician knowledge and behavior, system-level improvements in care processes, and, where feasible, patient-level outcomes such as access and quality of care. The evaluation process involves a formal review by a grant committee, which assesses proposals based on their alignment with implementation science principles, integration of education with clinical practice, and potential to achieve measurable improvements in patient care. Applicants may be contacted for additional information during the review process and will be notified of final decisions via email. This initiative reflects a structured and outcome-driven approach to advancing the adoption of CAR T-cell therapies through education and system-level change in community oncology settings.

Prioritize integration of education with operational change; define measurable outcomes; demonstrate sustainability beyond grant period; align with implementation science principles